DexCom, Inc. (NASDAQ:DXCM) – Jefferies Group dropped their Q4 2017 EPS estimates for shares of DexCom in a report released on Monday. Jefferies Group analyst R. Denhoy now expects that the medical device company will post earnings of $0.06 per share for the quarter, down from their prior forecast of $0.07. Jefferies Group has a “Buy” rating and a $91.00 price objective on the stock.

DexCom (NASDAQ:DXCM) last posted its earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.07. The business had revenue of $170.60 million for the quarter, compared to analyst estimates of $166.54 million. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The business’s quarterly revenue was up 24.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.24) EPS.

ILLEGAL ACTIVITY NOTICE: This report was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.americanbankingnews.com/2017/10/24/q4-2017-earnings-forecast-for-dexcom-inc-issued-by-jefferies-group-dxcm.html.

Several other research analysts have also commented on DXCM. BidaskClub downgraded shares of DexCom from a “buy” rating to a “hold” rating in a report on Wednesday, July 5th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $78.00 price objective on shares of DexCom in a report on Wednesday, July 12th. BMO Capital Markets reaffirmed a “buy” rating and set a $105.00 price objective on shares of DexCom in a report on Thursday, July 13th. Cowen and Company reaffirmed a “buy” rating and set a $90.00 price objective on shares of DexCom in a report on Friday, July 14th. Finally, Zacks Investment Research raised shares of DexCom from a “sell” rating to a “hold” rating in a report on Tuesday, July 18th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. DexCom presently has an average rating of “Buy” and a consensus price target of $72.19.

DexCom (NASDAQ DXCM) opened at 44.77 on Tuesday. The company’s 50 day moving average is $58.54 and its 200 day moving average is $69.03. DexCom has a 12-month low of $42.62 and a 12-month high of $88.80. The firm’s market cap is $3.88 billion.

Institutional investors and hedge funds have recently bought and sold shares of the business. Advisor Group Inc. increased its position in DexCom by 104.9% in the 2nd quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock valued at $119,000 after acquiring an additional 837 shares in the last quarter. IFP Advisors Inc increased its position in DexCom by 30.5% in the 2nd quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock valued at $178,000 after acquiring an additional 568 shares in the last quarter. Independent Portfolio Consultants Inc. increased its position in DexCom by 0.4% in the 2nd quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock valued at $183,000 after acquiring an additional 9 shares in the last quarter. Janney Montgomery Scott LLC increased its position in DexCom by 9.2% in the 2nd quarter. Janney Montgomery Scott LLC now owns 2,959 shares of the medical device company’s stock valued at $216,000 after acquiring an additional 250 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in DexCom by 12.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock valued at $238,000 after acquiring an additional 354 shares in the last quarter.

In related news, EVP Andrew K. Balo sold 3,244 shares of the stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $71.18, for a total transaction of $230,907.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Steven Robert Pacelli sold 1,450 shares of the stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $69.81, for a total transaction of $101,224.50. The disclosure for this sale can be found here. Insiders have sold a total of 21,573 shares of company stock valued at $1,524,286 in the last quarter. 1.70% of the stock is currently owned by corporate insiders.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.